A dual-readout F 2 assay that combines fluorescence resonance energy transfer and fluorescence polarization for monitoring bimolecular interactions

Assay and Drug Development Technologies

Volumn 9, Issue 4, 2011, Pages 382-393

  Du, Yuhong ^a   Nikolovska Coleska, Zaneta ^b   Qui, Min ^a   Li, Lian ^a   Lewis, Iestyn ^a   Dingledine, Raymond ^a   Stuckey, Jeanne A ^b,c   Krajewski, Krzysztof ^d   Roller, Peter P ^d   Wang, Shaomeng ^e   Fu, Haian ^a,f  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; PEPTIDE; PROTEIN INHIBITOR; PROTEIN MCL 1; PROTEIN NOXA; TETRAMETHYLRHODAMINE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PMAIP1 PROTEIN, HUMAN; PROTEIN BCL 2;

ARTICLE; ASSAY; COST; DUAL READOUT F2 ASSAY; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; MOLECULAR INTERACTION; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; QUALITY CONTROL; TECHNOLOGY; VALIDATION PROCESS; APOPTOSIS; BIOASSAY; DIAGNOSTIC PROCEDURES; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG EFFECT; DRUG SCREENING; ELECTRONICS; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MICROSCOPY; MOLECULAR LIBRARY; REPRODUCIBILITY; TIME;

APOPTOSIS; BIOLOGICAL ASSAY; CLINICAL LABORATORY TECHNIQUES; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROSCOPY; MINIATURIZATION; PROTO-ONCOGENE PROTEINS C-BCL-2; REPRODUCIBILITY OF RESULTS; SMALL MOLECULE LIBRARIES; TIME FACTORS;

EID: 80051844515     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2010.0292     Document Type: Article

References (35)

1. Wells JA, McClendon CL: Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450:1001-1009.
2. Jameson DM, Croney JC: Fluorescence polarization: Past, present and future. Comb Chem High Throughput Screen 2003;6:167-173.
3. Rich RL, Myszka DG: Advances in surface plasmon resonance biosensor analysis. Curr Opin Biotechnol 2000;11:54-61.
4. Selvin PR: The renaissance of fluorescence resonance energy transfer. Nat Struct Biol 2000;7:730-734.
5. Inglese J, Johnson RL, Simeonov A, et al.: High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 2007;3:466-479.
6. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.
7. Adams JM, Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science 1998;281:1322-1326.
8. Chao DT, Korsmeyer SJ: BCL-2 family: Regulators of cell death. Annu Rev Immunol 1998;16:395-419.
9. Petros AM, Medek A, Nettesheim DG, et al.: Solution structure of the antiapoptotic protein bcl-2. Proc Natl Acad Sci USA 2001;98:3012-3017.
10. Wuilleme-Toumi S, Robillard N, Gomez P, et al.: Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005;19:1248-1252.
11. Kaufmann SH, Karp JE, Svingen PA, et al.: Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998;91:991-1000.
12. Hussain SR, Cheney CM, Johnson AJ, et al.: Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: Down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res 2007;13:2144-2150.
13. Degterev A, Lugovskoy A, Cardone M, et al.: Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001;3:173-182.
14. Tzung SP, Kim KM, Basanez G, et al.: Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001;3:183-191.
15. Oltersdorf T, Elmore SW, Shoemaker AR, et al.: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-681.
16. Petros AM, Dinges J, Augeri DJ, et al.: Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem 2006;49:656-663.
17. Bruncko M, Oost TK, Belli BA, et al.: Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem 2007;50:641-662.
18. Wang G, Nikolovska-Coleska Z, Yang CY, et al.: Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006;49:6139-6142.
19. Tang G, Yang CY, Nikolovska-Coleska Z, et al.: Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. J Med Chem 2007;50: 1723-1726.
20. Tang G, Ding K, Nikolovska-Coleska Z, et al.: Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the antiapoptotic Bcl-2 proteins. J Med Chem 2007;50:3163-3166.
21. Tang G, Nikolovska-Coleska Z, Qiu S, Yang CY, Guo J, Wang S: Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins. J Med Chem 2008;51:717-720.
22. Tse C, Shoemaker AR, Adickes J, et al.: ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428.
23. Chen S, Dai Y, Harada H, Dent P, Grant S: Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007;67:782-791.
24. Chen L, Willis SN, Wei A, et al.: Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393-403.
25. Day CL, Smits C, Fan FC, Lee EF, Fairlie WD, Hinds MG: Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. J Mol Biol 2008;380:958-971.
26. Du Y, Masters SC, Khuri FR, Fu H: Monitoring 14-3-3 protein interactions with a homogeneous fluorescence polarization assay. J Biomol Screen 2006;11: 269-276.
27. Tetin SY, Hazlett TL: Optical spectroscopy in studies of antibody-hapten interactions. Methods 2000;20:341-361.
28. Rajkowski KM, Cittanova N: Corrected equations for the calculation of proteinligand binding results from fluorescence polarization data. J Theor Biol 1981; 93:691-696.
29. Ullman EF, Kirakossian H, Singh S, et al.: Luminescent oxygen channeling immunoassay: Measurement of particle binding kinetics by chemiluminescence. Proc Natl Acad Sci USA 1994;91:5426-5430.
30. Wu X, Glickman JF, Bowen BR, Sills MA: Comparison of assay technologies for a nuclear receptor assay screen reveals differences in the sets of identified functional antagonists. J Biomol Screen 2003;8:381-392.
31. Sills MA, Weiss D, Pham Q, Schweitzer R, Wu X, Wu JJ: Comparison of assay technologies for a tyrosine kinase assay generates different results in high throughput screening. J Biomol Screen 2002;7:191-214.
32. Wu X, Sills MA, Zhang JH: Further comparison of primary hit identification by different assay technologies and effects of assay measurement variability. J Biomol Screen 2005;10:581-589.
33. Du Y, Moulick K, Rodina A, et al.: High-throughput screening fluorescence polarization assay for tumor-specific Hsp90. J Biomol Screen 2007;12:915-924.
34. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
35. Turek-Etienne TC, Small EC, Soh SC, et al.: Evaluation of fluorescent compound interference in 4 fluorescence polarization assays: 2 kinases, 1 protease, and 1 phosphatase. J Biomol Screen 2003;8:176-184.